These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31323125)

  • 41. Tolvaptan for difficult- to -treat ascites: Difficulties in opening doors for GWAS application.
    Singh S; Roy A
    Liver Int; 2021 Dec; 41(12):3033. PubMed ID: 34486803
    [No Abstract]   [Full Text] [Related]  

  • 42. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.
    Kogiso T; Yamamoto K; Kobayashi M; Ikarashi Y; Kodama K; Taniai M; Torii N; Hashimoto E; Tokushige K
    Hepatol Res; 2017 Aug; 47(9):835-844. PubMed ID: 27670393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolvaptan add-on therapy and its effects on efficacy parameters and outcomes in patients hospitalized with heart failure.
    Kansara T; Gandhi H; Majmundar M; Kumar A; Patel JA; Kokkirala A; Moskovits N; Mushiyev S; Basman C
    Indian Heart J; 2022; 74(1):40-44. PubMed ID: 34919966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.
    Wang C; Xiong B; Cai L
    BMC Cardiovasc Disord; 2017 Jun; 17(1):164. PubMed ID: 28633650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment.
    Hirai K; Shimomura T; Moriwaki H; Ishii H; Shimoshikiryo T; Tsuji D; Inoue K; Kadoiri T; Itoh K
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1177-1183. PubMed ID: 27395406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites.
    Iwamoto T; Maeda M; Saeki I; Hidaka I; Tajima K; Ishikawa T; Takami T; Sakaida I
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1231-1235. PubMed ID: 30370940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery.
    Kerling A; Toka O; Rüffer A; Müller H; Habash S; Weiss C; Dittrich S; Moosmann J
    BMC Pediatr; 2019 Feb; 19(1):57. PubMed ID: 30755181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.
    Nakanishi H; Kurosaki M; Hosokawa T; Takahashi Y; Itakura J; Suzuki S; Yasui Y; Tamaki N; Nakakuki N; Takada H; Higuchi M; Komiyama Y; Yoshida T; Takaura K; Hayashi T; Kuwabara K; Sasaki S; Izumi N
    J Gastroenterol; 2016 Jun; 51(6):620-7. PubMed ID: 26610908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Tolvaptan on Volume Overload in Patients with Heart Failure.
    Kinugawa K; Sato N; Inomata T
    Int Heart J; 2018 Nov; 59(6):1368-1377. PubMed ID: 30369583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis.
    Iwamoto T; Maeda M; Hisanaga T; Saeki I; Fujisawa K; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
    Intern Med; 2016; 55(20):2911-2916. PubMed ID: 27746425
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Update of acute and long-term tolvaptan therapy.
    Imamura T; Kinugawa K
    J Cardiol; 2019 Feb; 73(2):102-107. PubMed ID: 30420105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Tolvaptan in a pediatric cardiorenal syndrome: What is its role?].
    Tejero Hernández MA; García Martínez E; Arroyo Marin MJ; Gómez Guzmán E
    Arch Argent Pediatr; 2018 Apr; 116(2):e279-e282. PubMed ID: 29557615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Durable response without recurrence to Tolvaptan improves long-term survival.
    Nakai M; Suda G; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Kawagishi N; Ohara M; Umemura M; Sho T; Morikawa K; Ogawa K; Sakamoto N
    J Gastroenterol; 2020 Dec; 55(12):1150-1161. PubMed ID: 32851487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting.
    Ohki T; Sato K; Yamada T; Yamagami M; Ito D; Kawanishi K; Kojima K; Seki M; Toda N; Tagawa K
    World J Hepatol; 2015 Jun; 7(12):1685-93. PubMed ID: 26140088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis.
    Kogiso T; Tokushige K; Hashimoto E; Ikarashi Y; Kodama K; Taniai M; Torii N; Shiratori K
    Hepatol Res; 2016 Mar; 46(3):E194-200. PubMed ID: 26123753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A selective oral vasopressin V2-receptor antagonist for patients with end-stage liver disease awaiting liver transplantation: a preliminary study.
    Kiritani S; Kaneko J; Miyata Y; Matsumura M; Akamatsu N; Ishizawa T; Arita J; Tamura S; Kokudo N; Hasegawa K
    Biosci Trends; 2019 May; 13(2):189-196. PubMed ID: 31019162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis.
    Wang L; Zhang Q; Liu M; Chen S; Han S; Li J; Du R
    J Int Med Res; 2019 Nov; 47(11):5414-5425. PubMed ID: 31680601
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
    Miyazaki M; Yada M; Tanaka K; Senjyu T; Goya T; Motomura K; Kohjima M; Kato M; Masumoto A; Kotoh K
    World J Gastroenterol; 2017 Aug; 23(29):5379-5385. PubMed ID: 28839438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
    Dahl E; Gluud LL; Kimer N; Krag A
    Aliment Pharmacol Ther; 2012 Oct; 36(7):619-26. PubMed ID: 22908905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.